Quetiapine (Seroquel) in the Treatment of Psychosis in Patients With Parkinson's Disease

Abstract

Psychoses are a common clinical problem in patients with Parkinson's disease. Treatment with typical neuroleptics or withdrawal of antiparkinsonian drugs may improve mental symptoms but will worsen the parkinsonism. Quetiapine (Seroquel), ICI 204,636, is a novel antipsychotic medication with a low potential for producing extrapyramidal side effects. In this open-label clinical study of 2 patients with Parkinson's disease, treatment with Seroquel successfully controlled psychotic symptoms without worsening of motor disability.

Pharmacologic Management of Agitation in Alzheimer’s Disease

“…Thirty percent of subjects experienced sedation, 15% developed orthostatic hypotension, and 12% experienced dizziness; these side effects were generally mild, early in the course of treatment, and transitory despite dose increases over time. The incidence of extrapyramidal signs and symptoms was low, consistent with encouraging pilot studies in patients with extrapyramidal disorders associated with dementia and/or psychosis [52]. Behavioral ratings suggested possible behavioral benefit.…”

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial

“…While other agents with the potential to treat dopamine-induced psychosis have been investigated, their possible efficacy is less well understood. In particular, olanzapine and quetiapine, 46 both new atypical antipsychotic agents, have been used to treat druginduced psychosis in PD, as has ondansetron, a 5HT3 receptor agonist. 47,48 However, they have not been adequately assessed in controlled trials.…”

Recognition and Management of Behavioral Disturbances in Dementia

“…119 Quetiapine was also found to be efficacious in patients with psychoses associated with Parkinson's disease. 120,121 Quetiapine carries the least risk for EPS, compared with risperidone and olanzapine, but it carries the risk of sedation and orthostatic hypotension. Orthostatic hypotension risk may be less if the starting dose is low (25 mg/day) and slowly increased.…”